Loss of NOX2 activity results in a disease called chronic granulomatous disease (CGD), characterized by an increased susceptibility to infections with fungi and with a subset of catalase‐positive bacteria (Goldblatt & Thrasher, 2000). Here, CYBB is linked to chronic granulomatous disease.